Viewing Study NCT02767804


Ignite Creation Date: 2025-12-24 @ 7:52 PM
Ignite Modification Date: 2026-03-12 @ 10:38 AM
Study NCT ID: NCT02767804
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2025-10-14
First Post: 2016-04-30
Is Gene Therapy: True
Has Adverse Events: False

Brief Title: eXalt3: Study Comparing X-396 (Ensartinib) to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients
Sponsor: Xcovery Holdings, Inc.
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module References Module